These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31540611)

  • 1. Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.
    Bertz JW; Epstein DH; Reamer D; Kowalczyk WJ; Phillips KA; Kennedy AP; Jobes ML; Ward G; Plitnick BA; Figueiro MG; Rea MS; Preston KL
    J Subst Abuse Treat; 2019 Nov; 106():43-57. PubMed ID: 31540611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
    Finan PH; Mun CJ; Epstein DH; Kowalczyk WJ; Phillips KA; Agage D; Smith MT; Preston KL
    Drug Alcohol Depend; 2020 Feb; 207():107698. PubMed ID: 31816489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
    Berro LF; Zamarripa CA; Talley JT; Freeman KB; Rowlett JK
    Addict Behav; 2022 Dec; 135():107433. PubMed ID: 35901553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
    Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
    JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
    Kowalczyk WJ; Moran LM; Bertz JW; Phillips KA; Ghitza UE; Vahabzadeh M; Lin JL; Epstein DH; Preston KL
    Am J Drug Alcohol Abuse; 2018; 44(5):502-511. PubMed ID: 29634425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
    Dunn KE; Finan PH; Andrew Tompkins D; Strain EC
    Addict Behav; 2018 Jan; 76():8-14. PubMed ID: 28735039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Subjective Sleep Problems in Men With Opioid Dependence Maintained on Buprenorphine.
    Tripathi R; Dhawan A; Rao R; Mishra AK; Jain R; Sinha S
    J Addict Med; 2020; 14(2):132-138. PubMed ID: 30964756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.
    King JB; Sainski-Nguyen AM; Bellows BK
    J Pain Palliat Care Pharmacother; 2016; 30(1):55-65. PubMed ID: 27007583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment.
    Ellis JD; Han D; Mayo J; Hobelmann JG; Finan PH; Huhn AS
    Br J Clin Pharmacol; 2024 Jun; 90(6):1408-1417. PubMed ID: 38417973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
    Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
    Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain and withdrawal are common among patients receiving medications for opioid use disorder and associated with pain catastrophizing, negative affect, and poor sleep.
    Berry MS; Dunn KE
    Exp Clin Psychopharmacol; 2024 Aug; 32(4):386-391. PubMed ID: 38722586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
    Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
    PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.